Dr. Ng on Immunotherapy in Micrometastatic High-Risk Soft Tissue Sarcoma

Video

Vincent Y. Ng, MD, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Vincent Y. Ng, MD, an assistant professor of orthopedics at the University of Maryland Medical Center, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Most patients with high-risk soft tissue sarcoma present with early-stage disease, explains Ng. The primary tumor can often be treated with radiation and surgery in a majority of cases, according to Ng.

The main issue faced in high-risk soft tissue sarcoma is how to address micrometastatic disease, says Ng. Prior attempts with chemotherapy and targeted therapy have not provided dramatic improvement. Based on what has been seen in other cancer types and in preliminary research for soft tissue sarcoma, neoadjuvant immunotherapy may be a potential treatment for micrometastatic high-risk soft tissue sarcoma, concludes Ng.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD